Study details
Enrolling now
A Phase 2a Study to Test Pegsitacianine for Imaging Cancer
University of Texas Southwestern Medical Center
NCT IDNCT05576974ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
120
Study length
about 3.7 years
Ages
18–99
Locations
1 site in TX
What this study is about
Researchers are testing whether Pegsitacianine, a drug that glows under special light, can be used to find head and neck cancers. The trial will give patients a single dose of the drug and see if it works to image tumors in their bodies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Pegsitacianine
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Pegsitacianine fluorescence imaging in HNSCC, UPC primary cancers that are HPV positive and HPV negative
Body systems
Oncology